NCT02192554

Brief Summary

To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2014

Typical duration for all trials

Geographic Reach
12 countries

84 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 15, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 17, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

April 30, 2018

Status Verified

April 1, 2018

Enrollment Period

2.9 years

First QC Date

July 15, 2014

Last Update Submit

April 27, 2018

Conditions

Keywords

OPC-34712brexpiprazoleDementiaAlzheimer's DiseaseCognitive DisordersMemoryAgitation

Outcome Measures

Primary Outcomes (2)

  • Adverse Events (AEs)

    Baseline to Month 2/Early Termination

  • Mini-Mental State Examination (MMSE) score

    Baseline to Month 2/Early Termination

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects must have completed a previous double-blind trial of brexpiprazole or placebo; neither drug or placebo will be administered in the trial

You may qualify if:

  • The investigator must assess the capacity of the subject to provide informed consent prior to enrollment and throughout the trial.
  • Male and female subjects who completed both the 12-week double-blind treatment period and the 30-day safety follow-up visit of the previous brexpiprazole trial.
  • Subject has an identified caregiver who is usually assigned to care for the subject on a regular basis, has sufficient contact to describe the subject's symptoms, and has direct observation of the subject's behavior.
  • Subject is able to comply with the protocol requirements.
  • Subjects who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (84)

Unknown Facility

Tuscaloosa, Alabama, 35404, United States

Location

Unknown Facility

Costa Mesa, California, 92626, United States

Location

Unknown Facility

Lakewood, California, 90805, United States

Location

Unknown Facility

Orange, California, 92868, United States

Location

Unknown Facility

Redlands, California, 92373, United States

Location

Unknown Facility

Bradenton, Florida, 34205, United States

Location

Unknown Facility

Hialeah, Florida, 33012, United States

Location

Unknown Facility

Hialeah, Florida, 33018, United States

Location

Unknown Facility

Miami, Florida, 33122, United States

Location

Unknown Facility

Miami, Florida, 33126, United States

Location

Unknown Facility

Miami, Florida, 33137, United States

Location

Unknown Facility

Miami, Florida, 33175, United States

Location

Unknown Facility

Miami Springs, Florida, 33166, United States

Location

Unknown Facility

North Miami, Florida, 33161, United States

Location

Unknown Facility

Orange City, Florida, 32763, United States

Location

Unknown Facility

Sarasota, Florida, 34239, United States

Location

Unknown Facility

Atlanta, Georgia, 30331, United States

Location

Unknown Facility

Suwanee, Georgia, 30024, United States

Location

Unknown Facility

Quincy, Massachusetts, 02169, United States

Location

Unknown Facility

St Louis, Missouri, 63128, United States

Location

Unknown Facility

Toms River, New Jersey, 08755, United States

Location

Unknown Facility

Brooklyn, New York, 11214, United States

Location

Unknown Facility

New Hyde Park, New York, 11040, United States

Location

Unknown Facility

Charlotte, North Carolina, 28270, United States

Location

Unknown Facility

Hickory, North Carolina, 28601, United States

Location

Unknown Facility

Raleigh, North Carolina, 27609, United States

Location

Unknown Facility

Dallas, Texas, 75243, United States

Location

Unknown Facility

Waukesha, Wisconsin, 53188, United States

Location

Unknown Facility

Burgas, 8000, Bulgaria

Location

Unknown Facility

Kardzhali, 6600, Bulgaria

Location

Unknown Facility

Rousse, 7003, Bulgaria

Location

Unknown Facility

Sofia, 1113, Bulgaria

Location

Unknown Facility

Sofia, 1431, Bulgaria

Location

Unknown Facility

Varna, 9020, Bulgaria

Location

Unknown Facility

Veliko Tarnovo, 5000, Bulgaria

Location

Unknown Facility

Penticton, British Columbia, V2A 4M4, Canada

Location

Unknown Facility

Kentville, Nova Scotia, B4N 4K9, Canada

Location

Unknown Facility

Zagreb, 10000, Croatia

Location

Unknown Facility

Zagreb, 10090, Croatia

Location

Unknown Facility

Bourg N Bresse, 01012, France

Location

Unknown Facility

Douai, 59500, France

Location

Unknown Facility

Élancourt, 78990, France

Location

Unknown Facility

Toulouse, 31059, France

Location

Unknown Facility

Mittweida, Saxony, 9648, Germany

Location

Unknown Facility

Berlin, 12209, Germany

Location

Unknown Facility

Bochum, 44791, Germany

Location

Unknown Facility

Cologne, 50935, Germany

Location

Unknown Facility

Westerstede, 26655, Germany

Location

Unknown Facility

Saint Petersburg, 190000, Russia

Location

Unknown Facility

Saint Petersburg, 190005, Russia

Location

Unknown Facility

Saint Petersburg, 191040, Russia

Location

Unknown Facility

Saint Petersburg, 191119, Russia

Location

Unknown Facility

Saint Petersburg, 192019, Russia

Location

Unknown Facility

Saint Petersburg, 195176, Russia

Location

Unknown Facility

Saint Petersburg, 197341, Russia

Location

Unknown Facility

Saint Petersburg, 198510, Russia

Location

Unknown Facility

Samara, 443016, Russia

Location

Unknown Facility

Saratov, 410060, Russia

Location

Unknown Facility

Tonnelniy, 357034, Russia

Location

Unknown Facility

Yekaterinburg, 620030, Russia

Location

Unknown Facility

Belgrade, 11000, Serbia

Location

Unknown Facility

Kovin, 26220, Serbia

Location

Unknown Facility

Kragujevac, 34000, Serbia

Location

Unknown Facility

Niš, 18000, Serbia

Location

Unknown Facility

Novi Kneževac, 23330, Serbia

Location

Unknown Facility

Novi Sad, 21000, Serbia

Location

Unknown Facility

Ljubljana, 1000, Slovenia

Location

Unknown Facility

Maribor, 2000, Slovenia

Location

Unknown Facility

Šempeter pri Gorici, 5290, Slovenia

Location

Unknown Facility

Pamplona, 31014, Spain

Location

Unknown Facility

Salamanca, 37004, Spain

Location

Unknown Facility

Valencia, 46010, Spain

Location

Unknown Facility

Valencia, 46026, Spain

Location

Unknown Facility

Zamora, 49021, Spain

Location

Unknown Facility

Kharkiv, 61068, Ukraine

Location

Unknown Facility

Kherson, 73488, Ukraine

Location

Unknown Facility

Kiev, 04080, Ukraine

Location

Unknown Facility

Kiev, 04114, Ukraine

Location

Unknown Facility

Lviv, 79021, Ukraine

Location

Unknown Facility

Odesa, 35006, Ukraine

Location

Unknown Facility

Odesa, 67513, Ukraine

Location

Unknown Facility

Poltava, 36013, Ukraine

Location

Unknown Facility

Vinnytsia, 21005, Ukraine

Location

Unknown Facility

Torpoint, PL11 2TB, United Kingdom

Location

MeSH Terms

Conditions

Mental DisordersNervous System DiseasesDementiaAlzheimer DiseaseCognitive DysfunctionPsychomotor Agitation

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNeurocognitive DisordersTauopathiesNeurodegenerative DiseasesCognition DisordersDyskinesiasNeurologic ManifestationsPsychomotor DisordersNeurobehavioral ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsAberrant Motor Behavior in DementiaBehavioral SymptomsBehavior

Study Officials

  • Eva Kohegyi, MD, MS

    Otsuka Pharmaceutical Development & Commercialization, Inc.

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 15, 2014

First Posted

July 17, 2014

Study Start

June 1, 2014

Primary Completion

May 1, 2017

Study Completion

May 1, 2017

Last Updated

April 30, 2018

Record last verified: 2018-04

Locations